New Step by Step Map For Imipenem
MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre review to evaluate many intravenous doses of sifalimumab, in Grownup sufferers with dermatomyositis or polymyositis (NCT00533091). Main trial targets were being To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis suff